Active — Not RecruitingNot Applicable

VIRTUUS Children's Study

United States445 participantsStarted 2017-08-10

Plain-language summary

The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.

Who can participate

Age range2 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males or females between 2 to 18 years at the time of recruitment * Receiving the first, or additional, incident kidney transplants. * Have an existing/prevalent transplant with a scheduled kidney allograft biopsy. * Parental/guardian permission (informed consent) and, if appropriate, child assent. Exclusion Criteria: • Patient's primary medical team feels the subject's participation is not safe.

What they're measuring

Amount of CD3E mRNA (CD3-epsilon polypeptide)

Timeframe: 48 months

Amount of CXCL10 (chemokine C-X-C motif ligand 10)

Timeframe: 48 months

Amount of 18s rRNA

Timeframe: 48 months

Trial details

NCT IDNCT03719339

SponsorChildren's Hospital of Philadelphia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-05-31

View on ClinicalTrials.gov More Renal Transplant Rejection trials